samedan logo

 
 
spacer
home > pmps > spring 2018 > supply network
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply Network

In an industry where the entire supply chain is faced with the regulatory requirement for serialisation and traceability, the solution needs large-scale integration and interoperability. For pharmaceutical businesses, the biggest challenge is how they orchestrate project implementation both internally and externally. In the Global Drug, Supply, Safety and Traceability report, just 48% of CMOs have integrated with a majority of brand owners, and just 41% of respondents stated that a high percentage of their internal packaging lines are ready for serialisation (1).

In every business, project leads must consider the overall complexity and scale of serialisation and traceability. They must understand and update internal processes and engage external partners before specifying and implementing a strategy and solution. While the pharma sector is well-versed at improving the performance of manufacturing and packing lines with new hardware and site-level systems, integrating with partners, each with their own policies and priorities, on the scale required by global serialisation and traceability is a completely new challenge. To complicate matters, the solution cannot be stationary – new products, partners, markets and regulations, customer requirements, and opportunities keep coming.

Managing all of these is hard work, but three core pillars of serialisation and traceability integration and interoperability in product supply networks can lead to success.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Pasi Kemppainen is the Principal Advisor on pharma digitalisation at Epista Life Science. He is currently leading Santen Pharmaceutical’s global serialisation and traceability programme. Prior to Epista Life Science, Pasi worked as Senior Consultant and Advisor for NNE – a Novo Nordisk engineering and consulting company. He also served as CEO at Original1 (a joint venture of SAP, Nokia, and Giesecke & Devrient – leaders in enterprise IT, mobile, and security), servicing a cloud and mobile platform for product serialisation, traceability, and consumer authentication services in Europe and China.
spacer
Pasi Kemppainen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

NDA Group welcomes Marianne Scheel Fjording, Ph.D. to the NDA Advisory Board adding essential expertise in bioanalysis and immunogenicity assessment to the team

Stockholm, Sweden – 7 March 2023 – Life Science Newswire – NDA Group is thrilled to announce the expansion of their Advisory Board with the appointment of Marianne Scheel Fjording, Ph.D. Marianne is a highly experienced expert in regulated bioanalysis and immunogenicity, with an emphasis on bioanalytical method development and validation of advanced biologics. She has a wealth of experience in the development of gene and cell therapies, engineered proteins, therapeutic antibodies, and derivatives, as well as biosimilars.
More info >>

White Papers
 
Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement